Page last updated: 2024-10-24

caffeine and Adrenocorticotropic Hormone, Inappropriate Secretion

caffeine has been researched along with Adrenocorticotropic Hormone, Inappropriate Secretion in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Osilodrostat (LCI699) is an adrenal steroidogenesis inhibitor currently in late-phase clinical development as a potential treatment for Cushing's disease."2.84Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults. ( Armani, S; Chun, DY; Darstein, C; Einolf, HJ; Gu, H; Kulkarni, S; Sauter, N; Ting, L; Tripathi, AP; Wang, L; Zhu, B, 2017)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Armani, S1
Ting, L1
Sauter, N1
Darstein, C1
Tripathi, AP1
Wang, L1
Zhu, B1
Gu, H1
Chun, DY1
Einolf, HJ1
Kulkarni, S1

Trials

1 trial available for caffeine and Adrenocorticotropic Hormone, Inappropriate Secretion

ArticleYear
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Clinical drug investigation, 2017, Volume: 37, Issue:5

    Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochr

2017